Traditional Chinese medicine composition for treating pulmonary interstitial fibrosis, traditional Chinese medicine decoction-free granule and application

Abstract

The invention relates to a traditional Chinese medicine composition for treating pulmonary interstitial fibrosis, a traditional Chinese medicine decoction-free granule and application, and belongs tothe technical field of traditional Chinese medicine. The traditional Chinese medicine composition is prepared from, by weight, 9-30 parts of crude radix astragali, 9-15 parts of radix codonopsis, 6-12parts of radix ophiopogonis, 10-15 parts of wax gourd kernels, 10-15 parts of rhizoma phragmitis, 9-30 parts of crude coix seeds, 5-10 parts of peach kernels, 6-15 parts of honeysuckle flowers, 6-15parts of radix angelicae sinensis and 2-6 parts of crude licorice roots. The traditional Chinese medicine decoction-free granule is prepared from the above-mentioned traditional Chinese medicine formula granules by weight. The invention discloses application of the traditional Chinese medicine composition and traditional Chinese medicine decoction-free granule in preparing medicine for treating the pulmonary interstitial fibrosis. The traditional Chinese medicine composition and the traditional Chinese medicine decoction-free granule have the advantages of benefiting qi, nourishing yin, eliminating phlegm and removing blood stasis, have the anti-inflammatory, anti-oxidation, anti-angiogenesis, anticoagulation, antithrombotic and anti-platelet agglutination functions, and have the functionof regulating the immune function of the body.

Description

technical field [0001] The invention belongs to the technical field of traditional Chinese medicine, and in particular relates to a traditional Chinese medicine composition for treating pulmonary interstitial fibrosis, traditional Chinese medicine decoction-free granules and applications thereof. Background technique [0002] Pulmonary interstitial fibrosis (PIF) is a progressive and progressive fatal diffuse lung disease involving pulmonary interstitium, alveoli and / or bronchioles. Hemoxemia, pulmonary function restrictive ventilatory disorder and decreased diffusion function are the clinical features, and the clinical manifestations are progressive dyspnea, shortness of breath, dry cough, etc., and most of the patients eventually die due to respiratory failure. Pulmonary interstitial fibrosis is divided into two categories: idiopathic pulmonary fibrosis (IPF) and secondary pulmonary fibrosis (IPF). Pulmonary fibrosis is often secondary to immune system diseases such as rh...

AI Technical Summary

Problems solved by technology

[0003] Pirfenidone, nintedanib, and antacid drugs are recommended for the treatment of pulmonary interstitial fibrosis by Western medicine. Oxygen therapy, mechanical ventilation, pulmonary rehabilitation, and lung transplantation can also be used for treatment. However, the clinical efficacy, safety and adaptability of Western medicine Further evaluation is needed, and western medicines are expensive, and are prone to adverse reactions such as elevated liver enzymes, photosensitivity, rash, fatigue, osteoporosis, and gastrointestinal disorders

Western medicine treatment summed up: basically no medicine available